Purchase Order 75N91021P00263

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $16,362.77 on February 26, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland, with an ultimate completion date of May 31, 2020. The order procures sequencing-related services or equipment from Illumina's portfolio of genomic analysis technologies and associated support.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $20,283.34 on April 24, 2020, for a service agreement with a firm fixed price. Work is performed in Bethesda, Maryland. The order is set to complete by July 19, 2020.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $16,085.00 on May 17, 2019, with ultimate completion on June 14, 2020. Performance occurs in Bethesda, Maryland. The order is a firm fixed price service agreement with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $12,130.80, with an award date of June 15, 2020 and ultimate completion date of June 20, 2021. Work is performed in San Diego, California. The order is for service agreement items on a firm fixed price basis with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $24,158.08 on October 19, 2017, with an ultimate completion date of November 19, 2018. Performance occurs at Bethesda, Maryland. The order is firm fixed price with no set-aside designation. Specific requirements are not detailed in the source material.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,987.00 on August 31, 2017, with final completion scheduled for March 19, 2018. Performance takes place in Bethesda, Maryland. The order covers sequencing instruments, reagents, consumables, or bioinformatics software—Illumina's core product portfolio for federal genomic research applications. Pricing is firm fixed price with no set-aside applied.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $20,198.50 in scientific equipment, effective February 9, 2021, with completion targeted March 31, 2021. Performance occurs in San Diego, California. The order is firm fixed-price with no set-aside designation.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $12,130.80 on June 11, 2020, with ultimate completion on June 14, 2021. The order covers a maintenance agreement on a firm fixed price basis. Work is performed in San Diego, California. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. for $3,978.82 on April 25, 2017, with ultimate completion on September 18, 2017. Work is performed at Bethesda, Maryland. The order is priced on a firm fixed price basis. No set-aside was used.</p>

<p>The National Cancer Institute awarded a purchase order to Illumina, Inc. valued at $13,253.75 on November 19, 2020, for the FY26 UDO Initiative.</p> <p>Performance takes place in Rockville, Maryland. The order is firm fixed price with no set-aside designation. Ultimate completion is scheduled for November 30, 2020.</p>